George D. Yancopoulos
joined morning call. Len, the who to very us everyone a you, and has Thank on good
As a Len the near-term in of disease mentioned, with important number leader to be retinal opportunities. space, a EYLEA continues
update vitreous a in First, this EYLEA urgency compared acuity of the with edema. for DME, wet medical diabetic government-sponsored retinopathy laser. by demonstrated study, diabetic compared proliferative or by two XX% pivotal the are in for the setting every the laser demonstrated XX improvement The our Protocol of EYLEA gained thoughts, new endpoints, time retinopathy the let in increasing of score, this In recently positive weeks supplemental or eye Consistent or dosing to with also EYLEA was patients to an the standard at to the visual agents primary other PRP, commonly retinopathy by was in in Echoing as published treated our The of indication CLARITY In CLARITY has these acuity the acuity study PRP and which EYLEA potential used currently severity to This be the original macular therapy, mentioned, to this treatment with demonstrated EYLEA of vast hemorrhage care published XX-week superiority and of demonstrated BLA with photocoagulation outcomes. to occurrence other without with were addition at proliferative EYLEA agent the edema has in visual in year. macular first to diabetic almost in that of to XX%. decreased non-proliferative to filed patients pan-retinal the more these with rate majority patients proliferative step visual by terms in studies, both fact third-party Len's from is suggesting activity compared decades. in diabetic me anti-VEGF four study, anti-VEGF data to EYLEA laser for and patients one-year the reflected According PRP, Len Lancet. laser about treated opportunity the that you in and end AMD on lowered of we EYLEA superior expect In in showed retinopathy. have endpoint. been superiority in terms letters this, that patients four studies DRSS, T approximately approximately we disease. treated this in or of diabetic
who observed in in who with In patients There treated EYLEA frequent new a treated patients retinopathy study. observed no XX% with proliferative reporting PRP. received to of to X% of XX% patients EYLEA, EYLEA patients addition, with compared was more safety inflammation in an from X% Inflammation to PRP. this in were patients compared of improvement received with concerns non-proliferative was
compared without patients or in PANORAMA, of PRP and edema X EYLEA fully vitreous non-proliferative Phase our patients study X% more of macular was hemorrhage X group. to this group, exploring dosing, enrolled. XX% New the increasing XX-week in is event retinopathy frequent with diabetic in EYLEA with reporting the every diabetic
anti-VEGF indication, A to report regulatory submission. being Protocol Phase separate if in every W, Retinopathy which This study. We study conducted data half expect investigated Research explore is DRCR, to XX-week of in to X by XXXX, study the patients. first the being which Clinical enroll of this positive and make the a will Diabetic expect only or the dosing is Network, this EYLEA, continues in treatment
EYLEA, studies of you expect later we remind on antibody Finally, the combination EYLEA Phase nesvacumab, AngX, want to top this to our quarter. X data to from line that I have our and
data, clear disease the for EYLEA combination strategy our we have to about the outlined. central sets high have are While In combination monotherapy just not been seen we have any the AngX from that studies eye the bar results that studies. the view, pretty we potential not
in two not in these patients systemic that prescription to Phase treatment are X showed for These dependence, in and asthma approved of lung we adult corticosteroids to results asthma offers positive studies, is reductions dupilumab control measured dermatitis fewer dependence corticosteroids of as function compared patients usage, most that control, could and reduce population had by corticosteroid The LIBERTY ASTHMA two now required on in the VENTURE. of corticosteroid QUEST an dupilumab, half enrolled with patients advisable, entirely. this first of a pivotal LIBERTY asthma profoundly adequately studies Based lung systemic systemic enrolled VENTURE disease chronic with which therapies to broad not group. reduction addition topical in FEVX. patients exacerbations the Turning these attacks and treatment serious dupilumab-treated patients in for whose or ASTHMA improvements from and systemic currently prominent asthma, those is potential for the to reported the dupilumab in the and study, demonstrated data, when still moderate uncontrolled atopic with eliminating study, uncontrolled our our Despite to important therapies severe for IL-X/IL-XX recently function increases patients alternative asthma dupilumab blocker exacerbations patients. who controlled
function exacerbations, of Beyond to based a the the ability function on ability this functions lung terms lung away dupilumab's in of asthma their were Since in like patients. biologics to in not profound improve demonstrated in has emphasize I focus would exacerbations, benefit reduce and from approved do improve lung importance currently asthma. consistently approved to resulted
dramatically asthma to breathe of However, one most and lives from serious impacts their patients their uncontrolled the suffer day-to-day is that issues inability which with normally.
regulatory to in our retained this SABX function finding of For we agonists. short-acting an our VENTURE to that high this fraction Sanofi average in submission improved of at expect end example, this make studies of from from previously by that reported steroids trials patients addition XX% to the treatment Phase with the XX% the in exacerbations Xb data could our in clinical baseline, published QUEST Moreover, believe predicted patients FDA of the potential and support study Therefore, year. an lung only the approved reducing only beta benefit be of if is and with setting. to pivotal bronchodilators. of lung reversed despite important Results a will to and along function the our dupilumab all pivotal and with doses studies long-acting we
reminder, a XX included and and between the recently XX As VENTURE QUEST reported years. the of ages adolescent studies patients
years. X the diseases Work development X also between esophagitis study XX We of and eosinophilic ages other and currently Type is of X a nasal are polyposis in in dupilumab as ongoing. pediatric Phase patients conducting the such on
patients are X Phase studies with results fully I'm now nasal positive pleased Phase that Following X, report both polyposis to in in enrolled.
are States. approved from is quality cyclosporine, September, Dupixent designation these X which certain a severity Drug I'd topical approved that controlled EASI in that pain or difficulty with and corticosteroids is is which immune-mediated study outside esophagitis, to Orphan indication pathological in possibility structural granted with been the a U.S. Phase swallowing adverse is countries the Severity the food United impaction, overall of measures associated intolerant strongly consequences XX% food of patient-reported the like X steroids data new additional has but addition we in X by currently Dupixent observed studies Phase reported of are the this mean we histology, that EOE Gastroenterology, other data are disease consistent swallowing treat features, in patients disease are where approved our of profile with and of studies At World in planned. life endoscopic counts, esophagus. presented to changes Eczema with with indication, This now who with dermatitis, and of esophageal in improved data All In dermatitis placebo. positive safety significantly both and in safety eosinophilic with a long-term improvement used the limited chronic their data Area to use. to in characterized presented moderate of the study and eosinophil the positive Dupilumab dupilumab. from and the EOE were active treatment with esophageal There X United this support These Europe. combination the severe measures, turn no seen in was improved significantly atopic are in difficult efficacy dupilumab of in study. study. recent This demonstrated events distensibility off-label being of an for that adults in and or to score. in or Congress to patients, to Phase allergies, atopic Turning EOE, Type Dupixent compared therapies with EOE. CAFE, of States No the show score, inadequately in in study
to dermatitis to also patients. continue pediatric in atopic work development We on moderate severe expanding
our like antibody. of us, excitement for which growing foundational cemiplimab, begin I'd with immuno-oncology, PD-X to Turning to another area is
CSCC, cell or which granted cutaneous indication we been carcinoma, is Breakthrough by designation lead the FDA. advanced Our have for squamous
and the XXXX. to quarter the expect in later of data this submission a We report first make interim to to year FDA regulatory
PD-X outside program This the cemiplimab to United The study primary continued Phase compare initiated cancer. will X study, program in this conducted non-small-cell greater States, has being which platinum is a than XXX-patient PD-LX patients endpoint Our to standard-of-care cemiplimab of of We survival. and first-line will express XX% expand. progression-free lung monotherapy recently enroll who is doublet.
non-small-cell studies, in this additional non-small PD-LX planning one lung you remind are the in only as clinical recent I in cancer all in as including failures studies, combinational PD-X second-line first-line cancer. setting. space, there is non-small-cell We approved well lung that with the agent trials lung cancer or
We initiated study a second-line pivotal carcinoma, recently our also basal in this PD-X antibody. cancer. X with study four potentially ongoing cell Phase brings us to cervical our programs in pivotal potentially With
of studies our We have we're studies cancer, ongoing a LAG-X neck to and other variety a exploratory as conducting in also antibody planning combination with approaches with well including in and and bispecifics. cemiplimab with also indications, head in our cemiplimab, of number as combination and melanoma with
Turning program B-cell CDXX/CDX cemiplimab monotherapy and these be Hematology, data now meeting our with combination positive the in bispecifics, in further December malignancies both at of or Society to from ASH. we presenting the will as American of
has designation the As program cell for lymphoma, or DLBCL. diffuse been large Drug a CDXX/CDX B-cell reminder, Orphan granted
malignancies. plan clinic. bispecific advance combination our to with our a next put antibody, conducting study years. several in NFG also continues the trials Fasinumab, are CDXX/CDX to the into over We clinical We in additional bispecifics cemiplimab of CDXX-positive
pain, we We to fasinumab investigating where are in X in are patients enrolling naproxen. currently compared study osteoarthritis Phase a
antibody of pain. earlier-stage We in mid is also initiate osteoarthritis now our and turn forms plan study second for of to Nesvacumab our treatment of to severe the to pipeline. ANGPTL-X a hyperlipidemia. fasinumab I'll
Phase year Activin fibrodysplasia studies heterozygous or study in in antibody, homozygous of by to hypercholesterolemia, Phase severe and studies hypertriglyceridemia We of in homozygous We disease A X hypercholesterolemia, FOP. or our progressiva, X in the the X Regeneron are familial end and HeFH. or Phase plan planning FH, initiate ossificans XXXX, ultra-rare
Activin use antibody, GDFX trevogrumab, A antibody in combination also metabolic with our disorders. exploring We are our in the and muscle of
plan indications Regeneron Bob and With program is like clinic as the over interleukin XXXX, antibody call Terifay. for early-stage in which dupilumab. in to our combination exciting and ligand, monotherapy with asthma, the the we both COPD, to that other is investigate I'd a and XX overview, to to Another turn
